Latest news with #PraderWilliSyndrome
The Sun
3 hours ago
- Entertainment
- The Sun
Katie Price gives update on Harvey's weight loss jabs after revealing he weighs almost 30st
KATIE Price has revealed son Harvey will "hopefully" start weight loss injections this week in an attempt to save his life. The former glamour model is worried about the disabled 22-year-old's health after his weight reached 30st. 5 5 Katie, 47, gave her fans an update on Harvey's weight loss journey on her podcast, The Katie Price Show, which she hosts with her sister, Sophie. Revealing her plans for the weekend, she said Harvey will be joining her on Saturday when she performs at Portsmouth Pride. Katie then added: "Hopefully Harvey starts his Mounjaro this week, but we'll talk about that next week and I'll go through all of what's happening about that." The mum-of-five previously opened up on how Harvey's life was at risk because of his size. The TV personality's eldest child has Prader-Willi syndrome, which sparks a constant desire to eat food and a permanent feeling of hunger which leads to obesity. In a video posted in April, Katie revealed: 'I'm so heartbroken and gutted that his weight is just going up. 'I just googled it in stones, 188kg is just a few kg of being 30 stone. 'It's so life-threatening now, I'm still waiting for the doctors to get back to me starting on the mounjaro and his journey to a healthy life.' She continued: 'It's so sad his quality of life at the moment where he's so big, he just can't really do much. Katie Price drops huge hint daughter Princess Andre is in talks for Love Island after boyfriend split 'It's just another thing I have to deal with because he's at high risk of having a heart attack, he struggles to put his trainers or struggles to walk anywhere but I love him and I'm going to help him through this. 'So sad, obesity and his condition is sad, it's sad to see someone go through it and he doesn't understand.' 5 Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. In February Katie told The Sun she consulted top doctors who suggested starting Harvey on the jabs in a bid to improve his chances of living longer. Harvey's biological dad is former footballer Dwight, 53, dated for a short period between 2000 and 2001, but split shortly after Katie told him she was pregnant. 5 5
The Sun
5 days ago
- General
- The Sun
UK landmarks glow orange to raise awareness of rare genetic condition
Some of the UK's most iconic landmarks were glowing orange last night - to raise awareness of a rare complex genetic condition that affects approximately 2,000 people in the UK. Lon don's Tower 42, Cardiff Castle, The Mersey Gateway Bridge and Green's Windmill in Nottingham were among the buildings to 'Glow Orange' to highlight Prader-Willi Syndrome (PWS). 4 4 4 Southend Civic Centre, Worcester's Guild Hall and Edinburgh's Camera Obscura and World of Illusions were also illuminated in an orange. The glow up lasted from sundown until sunrise, across 17 different landmarks, to mark the end of Prader-Willi Awareness month in May. Nigel Birrell, CEO of which was behind the activation and a proud charity partner with a scratchcard dedicated to the cause said: 'The Prader-Willi Syndrome Association (PWSA UK) is a cause that's very personal to me, and I've been a long-time admirer of the incredible work they carry out. "It's been truly inspiring to witness so many landmarks across the country light up in support of PWS awareness - the level of engagement has really touched us.' PWSA UK and FPWR UK (Foundation for Prader-Willi Research UK) have come together for a second year to plan and organise several events, which included one at the House of Lords on May 14th. Hosted in the capital city, it included speeches from both charities and the PWS community who shared their experience of living with the condition. The event also provided information to help people understand the complexities of PWS – the hope being that a better understanding will lead to more effective support which will save money and lives. The aim of the various events was to generate awareness and understanding of this rare condition which causes an overwhelming and uncontrollable drive to eat that can be life-limiting, as well as learning and physical difficulties. Together the charities are using the condition's initials to help people recognise key issues associated with the disorder. P - Persistent hunger which can lead to life-threatening obesity. W - Warning signs absent, typical health warning signs are absent for people with PWS. S – Specialist Care - people with the condition need specialist care, with round-the-clock supervision. Jackie Lodge of PWSA UK and Catherine Shaw of FPWR UK issued a joint statement. They said: 'We're delighted that PWSA UK and FPWR UK have come together again for PWS month to raise awareness for such an important cause. 'We want to generate as much awareness about PWS as possible and by these buildings and landmarks lighting up orange it is a fantastic way to do so, on top of the other events that have taken place this month. 'We're really grateful to these buildings for shining a light on this important cause.' 4
Yahoo
24-05-2025
- Business
- Yahoo
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets (formerly DCCR) to treat hyperphagia in Prader-Willi syndrome (PWS) for patients aged four and older. This follows the recent U.S. FDA approval of the drug, now marketed as VYKAT XR, marking it as the first approved therapy specifically targeting hyperphagia, the most life-limiting symptom of PWS, in both adults and children. A researcher studying cellular therapeutics under a microscope. PWS is a rare genetic disorder characterized by insatiable hunger, leading to dangerous food-seeking behaviors and severe health complications. Soleno Therapeutics, Inc. (NASDAQ:SLNO) estimates that about 9,500 PWS patients in the UK, France, Germany, Italy, and Spain could benefit from this therapy if approved in Europe. The company has also secured Orphan Drug Designation in the EU, potentially granting up to 10 years of market exclusivity. Soleno Therapeutics, Inc. (NASDAQ:SLNO)'s CEO, Dr. Anish Bhatnagar, emphasized the importance of this milestone in expanding access to a much-needed treatment for the PWS community across Europe. The company is working closely with regulators to expedite the availability of the therapy, which has shown promise in addressing a critical unmet need for patients and families. SLNO surged by over 61% in 2025 so far. While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) validated its Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets (formerly DCCR) to treat hyperphagia in Prader-Willi syndrome (PWS) for patients aged four and older. This follows the recent U.S. FDA approval of the drug, now marketed as VYKAT XR, marking it as the first approved therapy specifically targeting hyperphagia, the most life-limiting symptom of PWS, in both adults and children. A researcher studying cellular therapeutics under a microscope. PWS is a rare genetic disorder characterized by insatiable hunger, leading to dangerous food-seeking behaviors and severe health complications. Soleno Therapeutics, Inc. (NASDAQ:SLNO) estimates that about 9,500 PWS patients in the UK, France, Germany, Italy, and Spain could benefit from this therapy if approved in Europe. The company has also secured Orphan Drug Designation in the EU, potentially granting up to 10 years of market exclusivity. Soleno Therapeutics, Inc. (NASDAQ:SLNO)'s CEO, Dr. Anish Bhatnagar, emphasized the importance of this milestone in expanding access to a much-needed treatment for the PWS community across Europe. The company is working closely with regulators to expedite the availability of the therapy, which has shown promise in addressing a critical unmet need for patients and families. SLNO surged by over 61% in 2025 so far. While we acknowledge the potential of SLNO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLNO and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Sun
14-05-2025
- Automotive
- The Sun
Katie Price shows off brand new £40k car for Harvey – after he's unable to fit in hers
KATIE Price has shown off her brand new £40k car for Harvey, after he was unable to fit in hers. Harvey, 22, lives with Prader-Willi syndrome - a rare genetic condition which means he is always hungry - and currently weighs 28 stone. 4 4 And back in February, Katie admitted her son Harvey can't fit in her car after she revealed he will be starting weight loss jabs. She said at the time: "He's entitled to a mobility car because he doesn't fit into small cars because of his size. "Now the problem is they won't insure me as his carer because of my licence. "So that's another bridge I've got to overcome. I'm his mum and the one who will be driving him around." Now, the star has shown off his brand new set of wheels - A Volvo XC40 Mild Hybrid Plus Black Edition. With the motability scheme, Katie doesn't get the car for free but Harvey's disability benefits help pay towards the lease. She guided fans around on Snapchat as she told them she was trying to find a suitable car for her eldest son. After looking at a few different Volvos, the star said to fans: 'Want to see what car I've chosen for Harv?' She then reveals the Volvo in black and said: 'He's getting exactly this on a mobility scheme. Katie Price reveals harrowing ordeal with abusive ex who cut up her clothes 'This is the car, it's so nice, all black and you can fit a wheelchair in the back.' Katie also revealed that the seatbelts in the back would be big enough to go around him, and told fans of the importance of having that feature. The former glamour model explained that Harvey will move to his new house in August, and his new car will arrive that same month. In another car related update for Katie's kids, her daughter Princess just revealed that she'd passed her driving test. The excited teenager proudly her driving certificate while sitting in the car and beaming from ear to ear. Princess told her fans: 'I passed…🤭,' and she looked very proud of herself while donning a glam makeup look and blue top. Fans were delighted for the daughter of Katie and Peter Andre, and shared their messages of congratulations in the comments. One person penned: 'Brilliant! Well done,' and another said: 'Congratulations princess safe driving now.' Someone else added: 'Congrats I'm sure your dad will get you a decent car.' And Princess' auntie, Sophie Price, wrote: 'Yes Pringle,' followed by a string of hands in the air emojis. Meanwhile, Princess' mum Katie was disqualified from driving for two years in December 2021 after crashing her BMW in a drink-driving smash in Horsham. Katie was charged at Northampton Magistrates' Court for driving without insurance and without a valid driver's licence. Katie previously joked she would make her 17-year-old daughter become her chauffeur. She told us at the time of Princess passing her theory: "Princess has passed her theory, she's got to do her test now, then me and Princess in the car." "I messaged her and said I'm that close to getting you to be my driver." Katie has been banned from driving six times in the last ten years after a series of infringements.
